Neuroscience
A global development program testing RG6042, an anti-sense oligonucleotide, for the treatment of early manifest Huntington’s disease (HD)
Sep 16, 2018
Extract of the plenary session by Roche lead scientist Scott Schobel at EHDN 2018 outlining the design of the Global Development Program for RG6042 in HD. The slides made available are an extract of the plenary presentation and are a fair and balanced representation of the content presented.
Enter the password to open this PDF file:
File name:
-
File size:
-
Title:
-
Author:
-
Subject:
-
Keywords:
-
Creation Date:
-
Modification Date:
-
Creator:
-
PDF Producer:
-
PDF Version:
-
Page Count:
-
Preparing document for printing…
0%
Receive this presentation and more content via email
Related Content
-
Also In EHDN 2018:
A global development program testing RG6042, an anti-sense oligonucleotide, for the treatment of early manifest Huntington’s disease (HD)
-
Also In EHDN 2018:
How can progression of Huntington's disease (HD) be measured?
-
Also In EHDN 2018:
Huntington's Disease infographics